Status:
COMPLETED
Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy
Lead Sponsor:
Tatiana Aboulafia Brakha
Conditions:
Depression, Anxiety
Eligibility:
All Genders
18-50 years
Brief Summary
The main objective of this pilot study is to obtain preliminary data on the reactivity of salivary oxytocin during a single LSD intake as part of PAP treatment for anxiety disorders or depression (tre...
Eligibility Criteria
Inclusion
- ongoing psychotherapy with a certified psychotherapist, anxiety disorder or depression resistant to usual treatments, agreement to stop necessary medication
Exclusion
- Exclusion: psychotic or bipolar disorder, high suicidal risk, severe cardiovascular disease, severe liver disease, neurological disease of the central nervous system, pregnancy and breastfeeding
Key Trial Info
Start Date :
August 5 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 11 2024
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06557239
Start Date
August 5 2024
End Date
December 11 2024
Last Update
May 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Geneva University Hospitals
Geneva, Switzerland